trending Market Intelligence /marketintelligence/en/news-insights/trending/fssraxu7mfkr1ysz1sby0g2 content esgSubNav
In This List

ADMA Biologics investor to retire 19% stake

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


ADMA Biologics investor to retire 19% stake

ADMA Biologics Inc. said it will retire about 8.6 million common shares held by Biotest Pharmaceuticals Corp., which is divesting its U.S. assets.

The nonvoting shares represent about 19% of ADMA Biologics and will be transferred back to the company.

In June 2017, ADMA had issued 12.9 million of its shares as total consideration for buying Biotest's therapy business unit. The company, which had also transferred two of its plasma collection centers as part of the 2017 agreement, said it has the right to purchase the remaining shares for a certain period of time.

As it stands, Biotest can no longer name a director and observer to the ADMA Biologics board. Meanwhile, ADMA Biologics can no longer repurchase the two Georgia-based plasma collection centers, which will be transferred to Biotest on Jan. 1, 2019.

ADMA Biologics President and CEO Adam Grossman said the transaction simplifies the company's capital structure, reducing its total stock to 36.7 million shares from 45.3 million shares.